Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Comparing the cardiovascular therapeutic indices of glycopyrronium and tiotropium in an integrated rat pharmacokinetic, pharmacodynamic and safety model.

Trifilieff A, Ethell BT, Sykes DA, Watson KJ, Collingwood S, Charlton SJ, Kent TC.

Toxicol Appl Pharmacol. 2015 Aug 15;287(1):9-16. doi: 10.1016/j.taap.2015.05.012. Epub 2015 May 27.

PMID:
26026369
2.

The role of TRPM8 in the Guinea-pig bladder-cooling reflex investigated using a novel TRPM8 antagonist.

Gardiner JC, Kirkup AJ, Curry J, Humphreys S, O'Regan P, Postlethwaite M, Young KC, Kitching L, Ethell BT, Winpenny D, McMurray G.

Eur J Pharmacol. 2014 Oct 5;740:398-409. doi: 10.1016/j.ejphar.2014.07.022. Epub 2014 Jul 21.

PMID:
25058909
3.

Evaluation of Escherichia coli membrane preparations of canine CYP1A1, 2B11, 2C21, 2C41, 2D15, 3A12, and 3A26 with coexpressed canine cytochrome P450 reductase.

Locuson CW, Ethell BT, Voice M, Lee D, Feenstra KL.

Drug Metab Dispos. 2009 Mar;37(3):457-61. doi: 10.1124/dmd.108.025312. Epub 2008 Dec 12.

PMID:
19074522
4.

Glucuronidation of SN-38 and NU/ICRF 505 in human colon cancer and adjacent normal colon.

Cummings J, Ethell BT, Jardine L, Burchell B.

Anticancer Res. 2006 May-Jun;26(3B):2189-96.

5.

Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives.

Cummings J, Ethell BT, Jardine L, Boyd G, Macpherson JS, Burchell B, Smyth JF, Jodrell DI.

Cancer Res. 2003 Dec 1;63(23):8443-50.

6.
7.

Glucuronidation of HMR1098 in human microsomes: evidence for the involvement of UGT1A1 in the formation of S-glucuronides.

Ethell BT, Riedel J, Englert H, Jantz H, Oekonomopulos R, Burchell B.

Drug Metab Dispos. 2003 Aug;31(8):1027-34.

PMID:
12867491
8.

The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases.

Ethell BT, Anderson GD, Burchell B.

Biochem Pharmacol. 2003 May 1;65(9):1441-9.

PMID:
12732356
9.

Cloning and characterisation of the first drug-metabolising canine UDP-glucuronosyltransferase of the 2B subfamily.

Soars MG, Fettes M, O'Sullivan AC, Riley RJ, Ethell BT, Burchell B.

Biochem Pharmacol. 2003 Apr 15;65(8):1251-9.

PMID:
12694866
10.

Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases.

Ilett KF, Ethell BT, Maggs JL, Davis TM, Batty KT, Burchell B, Binh TQ, Thu le TA, Hung NC, Pirmohamed M, Park BK, Edwards G.

Drug Metab Dispos. 2002 Sep;30(9):1005-12.

PMID:
12167566
11.

Quantitative structure activity relationships for the glucuronidation of simple phenols by expressed human UGT1A6 and UGT1A9.

Ethell BT, Ekins S, Wang J, Burchell B.

Drug Metab Dispos. 2002 Jun;30(6):734-8.

PMID:
12019203
12.

Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation.

Cummings J, Boyd G, Ethell BT, Macpherson JS, Burchell B, Smyth JF, Jodrell DI.

Biochem Pharmacol. 2002 Feb 15;63(4):607-13.

PMID:
11992628
13.
14.

The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases.

Lautala P, Ethell BT, Taskinen J, Burchell B.

Drug Metab Dispos. 2000 Nov;28(11):1385-9.

PMID:
11038168
15.

A universal radiochemical high-performance liquid chromatographic assay for the determination of UDP-glucuronosyltransferase activity.

Ethell BT, Anderson GD, Beaumont K, Rance DJ, Burchell B.

Anal Biochem. 1998 Jan 1;255(1):142-7.

PMID:
9448853

Supplemental Content

Loading ...
Support Center